Fibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis
Open accessThe DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.
Abstract
The master cytokine TGF-β mediates tissue fibrosis associated with inflammation and tissue injury. TGF-β induces fibroblast activation and differentiation into myofibroblasts that secrete extracellular matrix proteins. Canonical TGF-β signaling mobilizes Smad2 and Smad3 transcription factors that control fibrosis by promoting gene expression. However, the importance of TGF-β-Smad2/3 signaling in fibroblast-mediated cardiac fibrosis has not been directly evaluated in vivo. Here, we examined pressure overload-induced cardiac fibrosis in fibroblast- and myofibroblast-specific inducible Cre-expressing mouse lines with selective deletion of the TGF-β receptors Tgfbr1/2, Smad2, or Smad3. Fibroblast-specific deletion of Tgfbr1/2 or Smad3, but not Smad2, markedly reduced the pressure overload-induced fibrotic response as well as fibrosis mediated by a heart-specific, latency-resistant TGF-β mutant transgene. Interestingly, cardiac fibroblast-specific deletion of Tgfbr1/2, but not Smad2/3, attenuated the cardiac hypertrophic response to pressure overload stimulation. Mechanistically, loss of Smad2/3 from tissue-resident fibroblasts attenuated injury-induced cellular expansion within the heart and the expression of fibrosis-mediating genes. Deletion of Smad2/3 or Tgfbr1/2 from cardiac fibroblasts similarly inhibited the gene program for fibrosis and extracellular matrix remodeling, although deletion of Tgfbr1/2 uniquely altered expression of an array of regulatory genes involved in cardiomyocyte homeostasis and disease compensation. These findings implicate TGF-β-Smad2/3 signaling in activated tissue-resident cardiac fibroblasts as principal mediators of the fibrotic response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overexpression of SMAD3 enhances, whereas knockdown inhibits αSMA and extracellular matrix production in fibroblasts (45–48). Furthermore, fibroblast-specific deletion of SMAD3 reduces αSMA production and myofibroblast phenotype (49–52), for example, loss of SMAD3 lowers the number of activated myofibroblasts in cardiac fibrosis in vivo and reduces extracellular matrix production by myofibroblasts”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [47]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“By contrast, cultured human primary cardiac and dermal fibroblasts and immortalized cardiac fibroblasts were relatively poor models of human cardiac fibroblast diversity under resting or stimulated (TGFβ (refs. 19,39,40), IL-1β (ref. 41)) conditions.”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“TGF-β1 activates SMAD2/3 signaling, driving pro-fibrotic gene expression and extracellular matrix deposition in cardiac fibroblasts [85].”
From A Paradigm Shift: Arrhythmogenic Cardiomyopathy Is an Inflammatory Disease (2026) · cites this paper as [85]
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, primary human cardiac fibroblasts, primary human dermal fibroblasts, and immortalized human cardiac fibroblasts were relatively poor models of human cardiac fibroblast diversity under resting or stimulated (TGFβ 20,33,34 , IL-1 β 35 ) conditions.”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“While numerous studies have implicated a role for TGFβ signaling in maladaptive cardiac remodeling and scar formation in HF 20,33”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [33]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591 · cited 1×
“Heart failure is an increasingly prevalent disease characterized by reduced cardiac output resulting from a progressive loss of cardiomyocytes, ventricular chamber remodeling, and accumulation of interstitial fibrosis (1).”
Smad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,373
Nagueh, S. F., Smiseth, O. A., Appleton, C. P., Byrd, B. F., Dokainish, H., Edvardsen, T., Flachskampf, F. A., Gillebert, T. C., Klein, A. L., Lancellotti, P., et al. (2016) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2016.01.011 · Cited by 5,262
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
TGF-β: the master regulator of fibrosis
Meng, X.-M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.48 · Cited by 3,528 · cited 1×
“Global TGF-β activity is upregulated in diseased hearts, where one of its primary actions is directed at the resident fibroblasts to alter the fibrotic response and ventricular remodeling (47, 48).”
Nagueh, S. F., Smiseth, O. A., Appleton, C. P., Byrd, B. F., Dokainish, H., Edvardsen, T., Flachskampf, F. A., Gillebert, T. C., Klein, A. L., Lancellotti, P., et al. (2016) · European Heart Journal – Cardiovascular Imaging · doi:10.1093/ehjci/jew082 · Cited by 2,425 · cited 1×
“The ratio of these measures ( E/e ′ ) was used as an indicator of diastolic function (60).”
Cardiac Fibroblast: The Renaissance Cell
Souders, C. A., Bowers, S. L. K., & Baudino, T. A. (2009) · Circulation Research · doi:10.1161/circresaha.109.209809 · Cited by 984 · cited 1×
“Progressive cardiac fibrosis in heart failure is predominantly mediated by the tissue-resident cardiac fibroblast, which becomes activated and then differentiated into a cell type referred to as the myofibroblast (5, 6).”
Transforming growth factor (TGF)-β signaling in cardiac remodeling
Dobaczewski, M., Chen, W., & Frangogiannis, N. G. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.10.033 · Cited by 934 · cited 1×
“TGF-β is considered a “master” cytokine/growth factor produced within injured or diseased tissues, where it activates fibroblasts and facilitates ECM production (15, 16).”
The role of TGF-β signaling in myocardial infarction and cardiac remodeling
BUJAK, M., & FRANGOGIANNIS, N. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.10.002 · Cited by 927
Genetic lineage tracing defines myofibroblast origin and function in the injured heart
Kanisicak, O., Khalil, H., Ivey, M. J., Karch, J., Maliken, B. D., Correll, R. N., Brody, M. J., J. Lin, S.-C., Aronow, B. J., Tallquist, M. D., et al. (2016) · Nature Communications · doi:10.1038/ncomms12260 · Cited by 892 · cited 6×
“Hence, here we used mice in which the Postn genetic locus was targeted with a tamoxifen-inducible MerCreMer (MCM) cDNA (29), and these mice were crossed with Smad2 fl/fl , Smad3 fl/fl , Smad2/3 fl/fl , and Tgfbr1/2 fl/fl targeted mice (Figure 2A).”
InfluentialSelf-citation
Cited by
CAR T cells produced in vivo to treat cardiac injury
Rurik, J. G., Tombácz, I., Yadegari, A., Méndez Fernández, P. O., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2022) · Science · doi:10.1126/science.abm0594 · Cited by 1,400
Transforming growth factor–β in tissue fibrosis
Frangogiannis, N. G. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190103 · Cited by 1,278
Frangogiannis, N. G. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa324 · Cited by 1,229
CAR T Cells Produced in vivo to Treat Cardiac Injury
Rurik, J. G., Tombácz, I., Yadegari, A., Fernández, P. O. M., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2023) · Book Publisher International (a part of SCIENCEDOMAIN International) · doi:10.9734/bpi/mono/978-81-19039-63-0/ch19 · Cited by 929
Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities
Frangogiannis, N. G. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.07.001 · Cited by 841
Signaling pathways and targeted therapy for myocardial infarction
Zhang, Q., Wang, L., Wang, S., Cheng, H., Xu, L., Pei, G., Wang, Y., Fu, C., Jiang, Y., He, C., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00925-z · Cited by 831
TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019
Dewidar, B., Meyer, C., Dooley, S., & Meindl-Beinker, A. N. (2019) · Cells · doi:10.3390/cells8111419 · Cited by 837
“[43], which again underlines the differential roles of SMAD2 and SMAD3 in mediating organ fibrosis.”
BackgroundZhang, M., Ma, Y., Ye, X., Zhang, N., Pan, L., & Wang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01464-x · Cited by 522
“TGF-β signaling underlies cardiac fibrosis.(184) Activation of TRPV3 was observed in stress-overloaded rats, and it upregulated protein expressions of collagen I, collagen III, TGF-β1, cyclin E, and cell cycle protein-dependent kinase 2 (CDK2).”
BackgroundAn acute immune response underlies the benefit of cardiac stem cell therapy
Vagnozzi, R. J., Maillet, M., Sargent, M. A., Khalil, H., Johansen, A. K. Z., Schwanekamp, J. A., York, A. J., Huang, V., Nahrendorf, M., Sadayappan, S., et al. (2020) · Nature · doi:10.1038/s41586-019-1802-2 · Cited by 554
Self-citationThe Extracellular Matrix in Ischemic and Nonischemic Heart Failure
Frangogiannis, N. G. (2019) · Circulation Research · doi:10.1161/circresaha.119.311148 · Cited by 520
Extracellular matrix remodeling and cardiac fibrosis
Li, L., Zhao, Q., & Kong, W. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.01.013 · Cited by 419
Fibroblasts in the Infarcted, Remodeling, and Failing Heart
Humeres, C., & Frangogiannis, N. G. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.02.006 · Cited by 410
“Moreover, TGF-b-driven activation of Smad-dependent signaling has been implicated in fibroblast activation in the pressureoverloaded heart (145).”
BackgroundFan, M., Yang, K., Wang, X., Chen, L., Gill, P. S., Ha, T., Liu, L., Lewis, N. H., Williams, D. L., & Li, C. (2023) · Science Advances · doi:10.1126/sciadv.adc9465 · Cited by 403
“Deficiency of either Smad2 or Smad3 ameliorates myofibroblast activation ( 50 ).”
Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets
Chen, R., Zhang, H., Tang, B., Luo, Y., Yang, Y., Zhong, X., Chen, S., Xu, X., Huang, S., & Liu, C. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01840-1 · Cited by 349
TGF-β-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases
Pardali, E., Sanchez-Duffhues, G., Gomez-Puerto, M., & Ten Dijke, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102157 · Cited by 360
“dissected the contribution of TGF-β activation in fibroblasts to fibrosis in the heart [154].”
BackgroundTransforming growth factor-β in myocardial disease
Frangogiannis, N. G. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00646-w · Cited by 344
Role of cytokines and inflammation in heart function during health and disease
Bartekova, M., Radosinska, J., Jelemensky, M., & Dhalla, N. S. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9716-x · Cited by 293
Targeting immune–fibroblast cell communication in heart failure
Amrute, J. M., Luo, X., Penna, V., Yang, S., Yamawaki, T., Hayat, S., Bredemeyer, A., Jung, I.-H., Kadyrov, F. F., Heo, G. S., et al. (2024) · Nature · doi:10.1038/s41586-024-08008-5 · Cited by 339
Immune Cells and Immunotherapy for Cardiac Injury and Repair
Rurik, J. G., Aghajanian, H., & Epstein, J. A. (2021) · Circulation Research · doi:10.1161/circresaha.121.318005 · Cited by 265
Molecular mechanisms of arrhythmogenic cardiomyopathy
Austin, K. M., Trembley, M. A., Chandler, S. F., Sanders, S. P., Saffitz, J. E., Abrams, D. J., & Pu, W. T. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0200-7 · Cited by 262
Ruiz-Villalba, A., Romero, J. P., Hernández, S. C., Vilas-Zornoza, A., Fortelny, N., Castro-Labrador, L., San Martin-Uriz, P., Lorenzo-Vivas, E., García-Olloqui, P., Palacio, M., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044557 · Cited by 260
Transforming Growth Factor-β Signaling in Fibrotic Diseases and Cancer-Associated Fibroblasts
Shi, X., Young, C. D., Zhou, H., & Wang, X.-J. (2020) · Biomolecules · doi:10.3390/biom10121666 · Cited by 243
“found that fibroblast-specific deletion of Tgfbr1, Tgfbr2, or Smad3, but not Smad2, significantly reduced α-SMA expression in mouse skin fibroblasts following stimulation of TGF-β1 in vitro and markedly reduced fibrosis in a cardiac mouse model [48].”
BackgroundThe gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases
Zhen, J., Zhou, Z., He, M., Han, H.-X., Lv, E.-H., Wen, P.-B., Liu, X., Wang, Y.-T., Cai, X.-C., Tian, J.-Q., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085041 · Cited by 229
“phosphorylated Smad3 bound to Smad4 (the partner Smad) and was transported from the cytoplasm to the nucleus to activate the transcription of downstream target genes related to ANP and bMHC (96).”
BackgroundMechanical regulation of gene expression in cardiac myocytes and fibroblasts
Saucerman, J. J., Tan, P. M., Buchholz, K. S., McCulloch, A. D., & Omens, J. H. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0155-8 · Cited by 221
Mitochondrial dysfunction in fibrotic diseases
Li, X., Zhang, W., Cao, Q., Wang, Z., Zhao, M., Xu, L., & Zhuang, Q. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-00316-9 · Cited by 224
The Pathogenesis of Cardiac Fibrosis: A Review of Recent Progress
Maruyama, K., & Imanaka-Yoshida, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052617 · Cited by 205
mRNA modifications in cardiovascular biology and disease: with a focus on m6A modification
Kumari, R., Ranjan, P., Suleiman, Z. G., Goswami, S. K., Li, J., Prasad, R., & Verma, S. K. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvab160 · Cited by 220
Complex Relationship Between Cardiac Fibroblasts and Cardiomyocytes in Health and Disease
Hall, C., Gehmlich, K., Denning, C., & Pavlovic, D. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019338 · Cited by 205
TGF-β Signaling: From Tissue Fibrosis to Tumor Microenvironment
Chung, J. Y.-F., Chan, M. K.-K., Li, J. S.-F., Chan, A. S.-W., Tang, P. C.-T., Leung, K.-T., To, K.-F., Lan, H.-Y., & Tang, P. M.-K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147575 · Cited by 200
Targeting the renin-angiotensin-aldosterone system in fibrosis
AlQudah, M., Hale, T. M., & Czubryt, M. P. (2020) · Matrix Biology · doi:10.1016/j.matbio.2020.04.005 · Cited by 191
Pivotal Role of TGF-β/Smad Signaling in Cardiac Fibrosis: Non-coding RNAs as Effectual Players
Saadat, S., Noureddini, M., Mahjoubin-Tehran, M., Nazemi, S., Shojaie, L., Aschner, M., Maleki, B., Abbasi-kolli, M., Rajabi Moghadam, H., Alani, B., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.588347 · Cited by 179
“It has been shown in mice that cardiac fibrosis related to pressure overload can be diminished by specific deletion of TGF-β1 or Smad3 gene in the triggered cardiac fibroblasts (CFs) (7).”
BackgroundTargeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
Sweeney, M., Corden, B., & Cook, S. A. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910865 · Cited by 195
“TAC-mediated myocardial fibrosis is enhanced in mice by transgenic overexpression of Nox4 (Kuroda et al, 2010), and cardiomyocyte-specific KO is protective against myocardial fibrosis and left ventricular dysfunction (Kuroda et al, 2010; Zhao et al, 2015).”
BackgroundInfluentialThe Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction
Packer, M. (2025) · JACC · doi:10.1016/j.jacc.2025.06.055 · Cited by 173
Mastikhina, O., Moon, B.-U., Williams, K., Hatkar, R., Gustafson, D., Mourad, O., Sun, X., Koo, M., Lam, A. Y. L., Sun, Y., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119741 · Cited by 185
The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
Timm, K. N., & Tyler, D. J. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-06941-x · Cited by 183
“TGFβ signalling increases the expression of SMAD2/3 transcription factors, leading to dedifferentiation of cardiac fibroblasts into cardiomyoblasts, which in turn secrete extracellular matrix proteins leading to cardiac fibrosis [57] and AMPK negatively regulates TGFβ signalling to act antifibrotically [58].”
BackgroundMacrophage Smad3 Protects the Infarcted Heart, Stimulating Phagocytosis and Regulating Inflammation
Chen, B., Huang, S., Su, Y., Wu, Y.-J., Hanna, A., Brickshawana, A., Graff, J., & Frangogiannis, N. G. (2019) · Circulation Research · doi:10.1161/circresaha.119.315069 · Cited by 180
TGF-β signaling: critical nexus of fibrogenesis and cancer
Giarratana, A. O., Prendergast, C. M., Salvatore, M. M., & Capaccione, K. M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05411-4 · Cited by 200
“This occurs in a few different ways, with TGF-β signaling acting on many different pathways responsible for ECM production and maintenance [38].”
BackgroundDynamic Chromatin Targeting of BRD4 Stimulates Cardiac Fibroblast Activation
Stratton, M. S., Bagchi, R. A., Felisbino, M. B., Hirsch, R. A., Smith, H. E., Riching, A. S., Enyart, B. Y., Koch, K. A., Cavasin, M. A., Alexanian, M., et al. (2019) · Circulation Research · doi:10.1161/circresaha.119.315125 · Cited by 179
Dynamic chromatin targeting of BRD4 stimulates cardiac fibroblast activation
(2019) · doi:10.1101/563445 · Cited by 179
Therapeutic targets for cardiac fibrosis: from old school to next-gen
Travers, J. G., Tharp, C. A., Rubino, M., & McKinsey, T. A. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148554 · Cited by 173
“Recent seminal findings have revealed the critical role for the profibrotic cytokine TGF-β in mediating tissue fibrosis, implicating both TGF-β receptors and SMAD2/3 as principal mediators of resident CF activation and pathological fibrotic remodeling (19).”
BackgroundOpposing Actions of Fibroblast and Cardiomyocyte Smad3 Signaling in the Infarcted Myocardium
Kong, P., Shinde, A. V., Su, Y., Russo, I., Chen, B., Saxena, A., Conway, S. J., Graff, J. M., & Frangogiannis, N. G. (2018) · Circulation · doi:10.1161/circulationaha.117.029622 · Cited by 173
Thbs1 induces lethal cardiac atrophy through PERK-ATF4 regulated autophagy
Vanhoutte, D., Schips, T. G., Vo, A., Grimes, K. M., Baldwin, T. A., Brody, M. J., Accornero, F., Sargent, M. A., & Molkentin, J. D. (2021) · Nature Communications · doi:10.1038/s41467-021-24215-4 · Cited by 175
Self-citationCardiac Fibrosis and Fibroblasts
Kurose, H. (2021) · Cells · doi:10.3390/cells10071716 · Cited by 171
“Macrophages in mice can be depleted by treatment with chlodronate liposomes [51].”
BackgroundTransforming growth factor-β signaling: From tissue fibrosis to therapeutic opportunities
Ren, L., Li, X., Duan, T., Li, Z.-H., Yang, J., Zhang, Y., Zou, L., Miao, H., & Zhao, Y. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110289 · Cited by 175
Trimethylamine N-Oxide Exacerbates Cardiac Fibrosis via Activating the NLRP3 Inflammasome
Li, X., Geng, J., Zhao, J., Ni, Q., Zhao, C., Zheng, Y., Chen, X., & Wang, L. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00866 · Cited by 160
“Importantly, TGF-β/Smad3 signaling has been implicated as a principal mediator of the fibrotic response associated with inflammation and tissue injury and could be regulated by NLRP3 in fibrotic disease as described in previous studies (Khalil et al., 2017; Tian et al., 2017).”
ResultContreras, O., Rossi, F. M. V., & Théret, M. (2021) · Skeletal Muscle · doi:10.1186/s13395-021-00265-6 · Cited by 175
Cardiac fibroblasts and mechanosensation in heart development, health and disease
Pesce, M., Duda, G. N., Forte, G., Girão, H., Raya, Á., Roca‐Cusachs, P., Sluijter, J. P. G., Tschöpe, C., & Linthout, S. V. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00799-2 · Cited by 166
Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling
Parichatikanond, W., Luangmonkong, T., Mangmool, S., & Kurose, H. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00034 · Cited by 174
“Even though the origin of the cells that underwent transformation has been debated (107), a recent study using fibroblast-specific, TGF-β signaling pathway knockout mice demonstrated that myofibroblasts in cardiac fibrosis are derived from resident fibroblasts, which activated via the TGF-β-Smad2/3 signaling pathway (…”
BackgroundUnraveling SSc Pathophysiology; The Myofibroblast
van Caam, A., Vonk, M., van den Hoogen, F., van Lent, P., & van der Kraan, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02452 · Cited by 153
Myocardial Interstitial Fibrosis in Nonischemic Heart Disease, Part 3/4
Díez, J., González, A., & Kovacic, J. C. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.019 · Cited by 157
Goh, K. Y., He, L., Song, J., Jinno, M., Rogers, A. J., Sethu, P., Halade, G. V., Rajasekaran, N. S., Liu, X., Prabhu, S. D., et al. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101100 · Cited by 149
Chromatin remodelling drives immune cell–fibroblast communication in heart failure
Alexanian, M., Padmanabhan, A., Nishino, T., Travers, J. G., Ye, L., Pelonero, A., Lee, C. Y., Sadagopan, N., Huang, Y., Auclair, K., et al. (2024) · Nature · doi:10.1038/s41586-024-08085-6 · Cited by 140
Self-citationRusso, I., Cavalera, M., Huang, S., Su, Y., Hanna, A., Chen, B., Shinde, A. V., Conway, S. J., Graff, J., & Frangogiannis, N. G. (2019) · Circulation Research · doi:10.1161/circresaha.118.314438 · Cited by 134
Blockade of Fibroblast YAP Attenuates Cardiac Fibrosis and Dysfunction Through MRTF-A Inhibition
Francisco, J., Zhang, Y., Jeong, J. I., Mizushima, W., Ikeda, S., Ivessa, A., Oka, S., Zhai, P., Tallquist, M. D., & Del Re, D. P. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.07.009 · Cited by 133
The role of Smad signaling cascades in cardiac fibrosis
Hanna, A., Humeres, C., & Frangogiannis, N. G. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109826 · Cited by 132
“Smad3-mediated myofibroblast conversion involves direct effects on α-SMA transcription [94], [96], and may be accentuated by indirect actions, such as upregulation of fibronectin [7], a specialized matrix protein that stimulates acquisition of a myofibroblast phenotype [97] or downregulation of the transcription facto…”
BackgroundResultMa, Y., Kuang, Y., Bo, W., Liang, Q., Zhu, W., Cai, M., & Tian, Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212341 · Cited by 138
“It has been reported that activated TGF-β1 binds to its receptors and induced collagen production through the Smad signaling cascades [15,17].”
BackgroundEndocardial Cell Plasticity in Cardiac Development, Diseases and Regeneration
Zhang, H., Lui, K. O., & Zhou, B. (2018) · Circulation Research · doi:10.1161/circresaha.117.312136 · Cited by 123
“tenuates injury-induced cellular expansion within the heart and the expression of fibrosis-mediating genes.(146) Thus, TGF-β/ Smad signaling may be a potential target for development of”
BackgroundUpregulation of Circular RNA CircNFIB Attenuates Cardiac Fibrosis by Sponging miR-433
Zhu, Y., Pan, W. Q., Yang, T., Meng, X., Jiang, Z., Tao, L., & Wang, L. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00564 · Cited by 124
“TGF-β signaling is the major mechanism mediating fibroblast proliferation (Dobaczewski et al., 2011; Kong et al., 2014; Khalil et al., 2017; Felisbino and Mckinsey, 2018).”
BackgroundSignaling Mechanisms of Myofibroblastic Activation: Outside-in and Inside-Out
Zent, J., & Guo, L.-W. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000493217 · Cited by 115
Chen, S., Zou, Y., Song, C., Cao, K., Cai, K., Wu, Y., Zhang, Z., Geng, D., Sun, W., Ouyang, N., et al. (2023) · Basic Research in Cardiology · doi:10.1007/s00395-023-01018-w · Cited by 132
“Previous studies have confirmed that TGF-β-Smad2/3 signaling in fibroblasts is a major mediator of the fibrotic response [115].”
ResultCrosstalk between TGF-β and WNT signalling pathways during cardiac fibrogenesis
Działo, E., Tkacz, K., & Błyszczuk, P. (2018) · Acta Biochimica Polonica · doi:10.18388/abp.2018_2635 · Cited by 110
“Fibroblast-specific deletion of Tgfbr1/2 or Smad3, but not Smad2, markedly reduced the pressure overload-induced fibrosis and inhibited synthesis of the ECM proteins (Khalil et al., 2017).”
BackgroundMesenchymal stem cells in fibrotic diseases—the two sides of the same coin
Qin, L., Liu, N., Bao, C.-L.-M., Yang, D.-Z., Ma, G.-X., Yi, W.-H., Xiao, G.-Z., & Cao, H.-L. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00952-0 · Cited by 114
“Specific inhibition of canonical TGFβ–Smad2/3 signaling in cardiac fibroblasts significantly reduces myofibroblast differentiation and cardiac hypertrophy [134].”
BackgroundQishen granule attenuates cardiac fibrosis by regulating TGF-β /Smad3 and GSK-3β pathway
Zeng, Z., Wang, Q., Yang, X., Ren, Y., Jiao, S., Zhu, Q., Guo, D., Xia, K., Wang, Y., Li, C., et al. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.152949 · Cited by 113
Chen, X., Jia, F., Li, Y., Deng, Y., Huang, Y., Liu, W., Jin, Q., & Ji, J. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119999 · Cited by 110
Wang, A. Z., Bowman-Kirigin, J. A., Desai, R., Kang, L.-I., Patel, P. R., Patel, B., Khan, S. M., Bender, D., Marlin, M. C., Liu, J., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01051-9 · Cited by 103
“” TGFβ stimulus has been shown to induce fibroblast activation and drive scarring in several organ systems [44, 45] and suggested perturbation of the fibroblasts.”
BackgroundWu, Y., Chang, T., Chen, W., Wang, X., Li, J., Chen, Y., Yu, Y., Shen, Z., Yu, Q., & Zhang, Y. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.08.031 · Cited by 104
Signaling cascades in the failing heart and emerging therapeutic strategies
He, X., Du, T., Long, T., Liao, X., Dong, Y., & Huang, Z. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00972-6 · Cited by 113
Cardiac Fibrosis in the Pressure Overloaded Left and Right Ventricle as a Therapeutic Target
Schimmel, K., Ichimura, K., Reddy, S., Haddad, F., & Spiekerkoetter, E. F. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.886553 · Cited by 108
Current understanding of fibrosis in genetic cardiomyopathies
Eijgenraam, T. R., Silljé, H. H. W., & de Boer, R. A. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.09.003 · Cited by 121
Kay, E. J., Koulouras, G., & Zanivan, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719922 · Cited by 95
Mechanisms of cardiac collagen deposition in experimental models and human disease
Cowling, R. T., Kupsky, D. F., Kahn, A. M., Daniels, L. B., & Greenberg, B. (2019) · Translational research · doi:10.1016/j.trsl.2019.03.004 · Cited by 113
Kim, D. K., Jeong, J., Lee, D. S., Hyeon, D. Y., Park, G. W., Jeon, S., Lee, K. B., Jang, J., Hwang, D., Kim, H. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33991-6 · Cited by 118
Chen, G., Xu, H., Xu, T., Ding, W., Zhang, G., Hua, Y., Wu, Y., Han, X., Xie, L., Liu, B., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154277 · Cited by 107
Bugyei‐Twum, A., Ford, C., Civitarese, R., Seegobin, J., Advani, S. L., Desjardins, J., Kabir, G., Zhang, Y., Mitchell, M., Switzer, J., et al. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy131 · Cited by 102
Cell-specific ablation of Hsp47 defines the collagen-producing cells in the injured heart
Khalil, H., Kanisicak, O., Vagnozzi, R. J., Johansen, A. K., Maliken, B. D., Prasad, V., Boyer, J. G., Brody, M. J., Schips, T., Kilian, K. K., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.128722 · Cited by 96
“Adult cardiomyocytes and interstitial heart cell fractions were isolated as described previously (55).”
BackgroundMethodInfluentialSelf-citationA Review of the Molecular Mechanisms Underlying Cardiac Fibrosis and Atrial Fibrillation
Sygitowicz, G., Maciejak, A., & Sitkiewicz, D. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194430 · Cited by 111
“A strong collagen synthesis stimulator is the TGF-β factor, which also participates in cardiac fibrosis process, contributing to differentiation of the fibroblasts into myofibroblasts, exerting its effect via the Smad signalling pathways [95,96].”
BackgroundSingh, R., Kaundal, R. K., Zhao, B., Bouchareb, R., & Lebeche, D. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105414 · Cited by 95
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript signaling, suggesting that it may very likely activate the fibrotic response via a different pathway independent of Smad3.”
BackgroundInfluentialZhou, Y., Zhang, Y., Jin, S., Lv, J., Li, M., & Feng, N. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117031 · Cited by 102
Hao, K., Lei, W., Wu, H., Wu, J., Yang, Z., Yan, S., Lu, X., Li, J., Xia, X., Han, X., et al. (2019) · Theranostics · doi:10.7150/thno.33920 · Cited by 95
“In response to tissue injury, TGF-β activates fibroblast proliferation and differentiation into myofibroblast through both canonical and non-canonical TGF-β signaling [5, 6].”
The Role of Cyclic AMP Signaling in Cardiac Fibrosis
Delaunay, M., Osman, H., Kaiser, S., & Diviani, D. (2019) · Cells · doi:10.3390/cells9010069 · Cited by 97
“, p38) pathways in the initiation and propagation of cardiac fibrosis in diseased hearts [22,24].”
BackgroundWang, B., Wang, H., Zhang, M., Ji, R., Wei, J., Xin, Y., & Jiang, X. M. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15479 · Cited by 99
Patrick, R., Janbandhu, V. C., Tallapragada, V. J., Tan, S. S. M., McKinna, E. E., Contreras, O., Ghazanfar, S., Humphreys, D. T., Murray, N. J., Tran, T. H. Y., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk8501 · Cited by 99
The cGMP system: components and function
Hofmann, F. B. (2019) · Biological Chemistry · doi:10.1515/hsz-2019-0386 · Cited by 88
“…and cGKIα are present at relatively high concentrations in the MF, where they reduce the activation of fibroblasts during cardiac remodeling most likely caused by an inhibition of transforming growth factor (TGF)β1 signaling (Buxton and Duan, 2008; Rainer et al., 2014; Khalil et al., 2017).”
BackgroundNon-ischemic dilated cardiomyopathy and cardiac fibrosis
Cojan-Minzat, B. O., Zlibut, A., & Agoşton-Coldea, L. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09940-0 · Cited by 94
“Conversely, profibrotic conditions are able to activate the AMP-activated protein kinase α pathway which can antagonize SMAD3, counteracting its profibrotic effects [6, 10, 36, 37] [37].”
BackgroundMongirdienė, A., Skrodenis, L., Varoneckaitė, L., Mierkytė, G., & Gerulis, J. (2022) · Biomedicines · doi:10.3390/biomedicines10030602 · Cited by 90
“Some studies have found that SIRT3 is involved in cardiac muscle hypertrophy and fibrosis, leading eventually to CHF development [89,90].”
BackgroundBone Morphogenetic Protein 9 Reduces Cardiac Fibrosis and Improves Cardiac Function in Heart Failure
Morine, K., Qiao, X., York, S., NATOV, P. S., Paruchuri, V., Zhang, Y., Aronovitz, M. J., Karas, R. H., & Kapur, N. K. (2018) · Circulation · doi:10.1161/circulationaha.117.031635 · Cited by 89
Bello, L., & Pegoraro, E. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050649 · Cited by 83
“TGFβ is a well-known driver of dilative ventricular remodeling in dystrophic and non-dystrophic cardiomyopathies, as it stimulates myocardial fibrosis [104,105], and angiotensin-converting enzyme inhibitors (ACEi) are effective against cardiac remodeling, because they block downstream TGFβ activation [106].”
BackgroundFibroblast GSK-3α Promotes Fibrosis via RAF-MEK-ERK Pathway in the Injured Heart
Umbarkar, P., Tousif, S., Singh, A. P., Anderson, J. C., Zhang, Q., Tallquist, M. D., Woodgett, J. R., & Lal, H. (2022) · Circulation Research · doi:10.1161/circresaha.122.321431 · Cited by 88
Zheng, D., Zhang, Y., Hu, Y., Guan, J. Z., Xu, L., Xiao, W., Zhong, Q., Ren, C., Lü, J., Liang, J., et al. (2019) · FEBS Journal · doi:10.1111/febs.14780 · Cited by 82
Induction of LOX by TGF‐β1/Smad/AP‐1 signaling aggravates rat myocardial fibrosis and heart failure
Lu, M., Qin, Q., Yao, J., Sun, L., & Qin, X. (2019) · IUBMB Life · doi:10.1002/iub.2112 · Cited by 82
“Canonical TGF-β signaling mobilizes Smad2 and Smad3 transcription factors that control fibrosis by promoting gene expression.(19) TGF-β1/Smad2/3 signaling has been shown to contribute to myocardial fibrosis.”
BackgroundLi, S., Ding, X., Zhang, H., Ding, Y., & Tan, Q. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108605 · Cited by 86
Myocardial Fibrosis in Hypertrophic Cardiomyopathy: A Perspective from Fibroblasts
Schlittler, M., Pramstaller, P. P., Rossini, A., & Bortoli, M. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914845 · Cited by 86
“The deletion of Smad2/3 and Smad3 in the cFB population significantly reduced pressure overload- and TGF-β-induced fibrosis, whereas the deletion of Smad2/3 from cardiomyocytes had no effect on the development of fibrosis [51].”
Cibi, D. M., Bi-Lin, K. W., Shekeran, S. G., Sandireddy, R., Tee, N., Singh, A., Wu, Y., Srinivasan, D. K., Kovalik, J., Ghosh, S., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108288 · Cited by 83
Defining cardiac functional recovery in end-stage heart failure at single-cell resolution
Amrute, J. M., Lai, L., Ma, P., Koenig, A. L., Kamimoto, K., Bredemeyer, A., Shankar, T. S., Kuppe, C., Kadyrov, F. F., Schulte, L. J., et al. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00260-8 · Cited by 79
“Interestingly, cardiac recovery was associated with reduced expression of genes associated with inflammatory and TGF-β signaling in cardiac fibroblasts and markers of immune-cell-driven fibroblast activation 22,55 .”
BackgroundCardiac Fibroblasts and the Extracellular Matrix in Regenerative and Nonregenerative Hearts
Hortells, L., Johansen, A. K. Z., & Yutzey, K. E. (2019) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd6030029 · Cited by 79
“For example, Wnt/β-catenin signaling, which is critical during cardiac development and is increased in diseased hearts [84], was found to be necessary for pathologic fibroblast activation and proliferation in response to transverse aortic constriction (TAC) [60] and cardiac ischemia [85].”
BackgroundInfluentialPlatelet-derived growth factor receptor-α is essential for cardiac fibroblast survival
Ivey, M. J., Kuwabara, J. T., Riggsbee, K. L., & Tallquist, M. D. (2019) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00054.2019 · Cited by 85
Huang, S., Chen, B., Su, Y., Alex, L., Humeres, C. D., Shinde, A. V., Conway, S. J., & Frangogiannis, N. G. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.05.006 · Cited by 81
Ge, Z., Yin, C., Li, Y., Ding, T., Yin, X., Li, Q., Tang, Y. M., & Zhang, Y. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-021-03211-8 · Cited by 77
Zhu, D., Liu, S., Huang, K., Li, J., Mei, X., Li, Z., & Cheng, K. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad114 · Cited by 83
WWP2 regulates pathological cardiac fibrosis by modulating SMAD2 signaling
Chen, H., Moreno‐Moral, A., Pesce, F., Devapragash, N., Mancini, M., Heng, E. L., Rotival, M., Srivastava, P. K., Harmston, N., Shkura, K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11551-9 · Cited by 95
Metadata
- Authors
- Khalil, H., Kanisicak, O., Prasad, V., Correll, R. N., Fu, X., Schips, T., Vagnozzi, R. J., Liu, R., Huynh, T., Lee, S.-J., Karch, J., & Molkentin, J. D.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- Johns Hopkins University (US)
- Corresponding author
- Molkentin, Jeffery D.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2017-09-11
- Volume
- 127
- Issue
- 10
- Pages
- 3770-3783
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5617658
- OpenAlex
- W2750808153
- Cited by
- 905
- References
- 64
- Citations by year
- 2026: 92 · 2025: 102 · 2024: 128 · 2023: 121 · 2022: 144 · 2021: 110 · 2020: 84 · 2019: 85 · 2018: 34 · 2017: 2
- FWCI
- 43.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Civil War Book Review (submittedVersion)
- Language arts journal of Michigan (submittedVersion)
- Funders
- National Science Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (158486, 148429)
- National Institutes of Health
- National Heart, Lung, and Blood Institute (P01HL069779, R01HL105924)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR060636)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Keywords
- myocardial fibrosis, TGF-beta signaling, Smad2, Smad3, cardiac fibroblasts, myofibroblasts, TGF-beta receptor, pressure overload, cardiac hypertrophy, extracellular matrix remodeling
- MeSH terms
- Receptor, Transforming Growth Factor-beta Type I, Receptor, Transforming Growth Factor-beta Type II, Animals, Fibrosis, Heart Diseases, Male, Mice, Transgenic, Myocardium, Organ Specificity, Signal Transduction, Transforming Growth Factor beta, Protein Serine-Threonine Kinases, Gene Deletion, Receptors, Transforming Growth Factor beta, Myocytes, Cardiac, Mice, Smad2 Protein, Smad3 Protein, Myofibroblasts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.